See more : NSX Limited (NSX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of InfuSystem Holdings, Inc. (INFU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InfuSystem Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Penguin Solutions, Inc. (PENG) Income Statement Analysis – Financial Results
- UniCredit S.p.A. (CRIN.DE) Income Statement Analysis – Financial Results
- CFSB Bancorp, Inc. (CFSB) Income Statement Analysis – Financial Results
- Excelsior Medical Co., Ltd. (4104.TW) Income Statement Analysis – Financial Results
- J.E.T. Co., Ltd. (6228.T) Income Statement Analysis – Financial Results
InfuSystem Holdings, Inc. (INFU)
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.79M | 109.91M | 102.38M | 97.39M | 81.12M | 67.14M | 71.08M | 70.50M | 72.13M | 66.49M | 62.28M | 58.83M | 54.64M | 47.23M | 38.96M | 35.42M | 6.58M | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 47.34M | 42.19M | 38.63M | 34.23M | 28.12M | 27.72M | 25.76M | 20.94M | 19.13M | 18.60M | 15.92M | 19.28M | 13.68M | 10.33M | 9.19M | 1.62M | 0.00 | 0.00 |
| Gross Profit | 63.11M | 62.57M | 60.20M | 58.76M | 46.88M | 39.02M | 43.36M | 44.74M | 51.18M | 47.35M | 43.68M | 42.91M | 35.36M | 33.55M | 28.64M | 26.22M | 4.96M | 0.00 | 0.00 |
| Gross Profit Ratio | 50.17% | 56.93% | 58.80% | 60.33% | 57.80% | 58.12% | 61.01% | 63.46% | 70.97% | 71.22% | 70.13% | 72.94% | 64.71% | 71.03% | 73.50% | 74.05% | 75.39% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 45.38M | 46.08M | 42.26M | 35.20M | 29.02M | 24.85M | 25.20M | 24.63M | 23.78M | 19.99M | 18.97M | 23.06M | 17.99M | 20.62M | 12.22M | 11.77M | 4.89M | 919.22B | 0.00 |
| Selling & Marketing | 12.65M | 12.26M | 10.78M | 9.66M | 9.93M | 9.11M | 9.78M | 9.66M | 10.42M | 9.75M | 9.66M | 9.86M | 9.37M | 7.09M | 5.26M | 4.66M | 649.00K | -919.20B | 0.00 |
| SG&A | 58.03M | 58.34M | 53.04M | 44.86M | 38.96M | 33.95M | 34.98M | 34.29M | 34.20M | 29.73M | 28.63M | 32.93M | 27.36M | 27.71M | 17.48M | 16.42M | 6.12M | 20.82M | 24.48K |
| Other Expenses | 990.00K | 2.58M | 4.34M | 5.08M | 4.40M | -37.00K | -113.00K | 6.00K | 13.00K | 13.00K | 301.00K | -141.00K | 6.76M | 6.77M | 5.83M | 5.01M | 6.46M | 20.82M | 0.00 |
| Operating Expenses | 59.02M | 60.92M | 57.38M | 49.93M | 43.36M | 38.60M | 46.18M | 43.77M | 42.32M | 38.02M | 37.78M | 40.91M | 34.12M | 34.48M | 23.31M | 21.44M | 6.46M | 20.82M | 24.48K |
| Cost & Expenses | 121.70M | 108.26M | 99.56M | 88.56M | 77.59M | 66.72M | 73.90M | 69.52M | 63.26M | 57.16M | 56.38M | 56.83M | 53.40M | 48.17M | 33.64M | 30.63M | 8.08M | 20.82M | 24.48K |
| Interest Income | 0.00 | 1.40M | 1.38M | 1.26M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 36.00K | 3.88M | 3.20M | 0.00 |
| Interest Expense | 2.17M | 1.40M | 1.38M | 1.26M | 1.90M | 1.42M | 1.33M | 1.34M | 1.71M | 3.13M | 3.50M | 3.34M | 2.19M | 3.35M | 3.50M | 3.77M | 774.00K | 1.30K | 300.00 |
| Depreciation & Amortization | 12.51M | 13.36M | 14.63M | 14.03M | 12.34M | 11.31M | 12.52M | 10.74M | 8.24M | 6.14M | 8.03M | 8.40M | 9.05M | 8.60M | 6.44M | 6.40M | 862.00K | 6.66M | 0.00 |
| EBITDA | 16.50M | 15.09M | 17.15M | 22.82M | 15.77M | 11.69M | 8.60M | 11.72M | 13.94M | 15.49M | 14.23M | 9.45M | -57.34M | 7.75M | 11.69M | 20.40M | -635.00K | -6.82M | -24.48K |
| EBITDA Ratio | 13.11% | 13.55% | 16.86% | 23.44% | 19.44% | 17.41% | 13.49% | 16.63% | 23.74% | 23.29% | 22.85% | 17.44% | 18.82% | 16.21% | 30.22% | 31.70% | 40.40% | 0.00% | 0.00% |
| Operating Income | 4.09M | 1.65M | 2.82M | 8.83M | 3.53M | 415.00K | -3.81M | 974.00K | 8.86M | 9.33M | 5.90M | 2.00M | -66.36M | -938.00K | 5.33M | 4.79M | -1.50M | -20.82M | -24.48K |
| Operating Income Ratio | 3.25% | 1.50% | 2.75% | 9.06% | 4.35% | 0.62% | -5.36% | 1.38% | 12.29% | 14.03% | 9.47% | 3.40% | -121.45% | -1.99% | 13.67% | 13.51% | -22.74% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.24M | -1.52M | -1.56M | -1.28M | -2.00M | -1.46M | -1.45M | -1.34M | -3.29M | -3.12M | -3.20M | -4.15M | -2.22M | -2.29M | -3.58M | 6.08M | -189.00K | -6,821.45B | 0.00 |
| Income Before Tax | 1.85M | 130.00K | 1.26M | 7.54M | 1.52M | -1.04M | -5.26M | -364.00K | 5.57M | 6.21M | 2.70M | -2.15M | -68.58M | -3.22M | 1.75M | 10.87M | -1.69M | -6.82M | 0.00 |
| Income Before Tax Ratio | 1.47% | 0.12% | 1.23% | 7.75% | 1.88% | -1.55% | -7.40% | -0.52% | 7.73% | 9.34% | 4.34% | -3.66% | -125.51% | -6.82% | 4.49% | 30.68% | -25.62% | 0.00% | 0.00% |
| Income Tax Expense | 979.00K | 112.00K | -163.00K | -9.79M | 163.00K | 53.00K | 15.45M | -142.00K | 1.83M | 2.85M | 1.03M | -663.00K | -23.13M | -1.37M | 977.00K | 907.00K | 1.11M | 1.04M | 24.78K |
| Net Income | 872.00K | 18.00K | 1.42M | 17.33M | 1.36M | -1.10M | -20.71M | -222.00K | 3.74M | 3.36M | 1.67M | -1.49M | -45.44M | -1.85M | 774.00K | 9.96M | -2.80M | -7.86M | -24.78K |
| Net Income Ratio | 0.69% | 0.02% | 1.39% | 17.80% | 1.68% | -1.63% | -29.13% | -0.31% | 5.19% | 5.05% | 2.68% | -2.53% | -83.17% | -3.92% | 1.99% | 28.12% | -42.48% | 0.00% | 0.00% |
| EPS | 0.04 | 0.00 | 0.07 | 0.86 | 0.07 | -0.05 | -0.91 | -0.01 | 0.17 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 | 0.56 | -0.15 | -0.58 | -0.01 |
| EPS Diluted | 0.04 | 0.00 | 0.06 | 0.80 | 0.07 | -0.05 | -0.91 | -0.01 | 0.16 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 | 0.53 | -0.15 | -0.58 | -0.01 |
| Weighted Avg Shares Out | 21.02M | 20.65M | 20.52M | 20.11M | 19.73M | 21.42M | 22.74M | 22.20M | 22.41M | 22.15M | 21.87M | 21.27M | 21.07M | 19.72M | 18.61M | 17.94M | 18.30M | 13.66M | 3.25M |
| Weighted Avg Shares Out (Dil) | 21.65M | 21.55M | 22.05M | 21.72M | 20.84M | 21.42M | 22.74M | 22.62M | 22.84M | 22.55M | 22.07M | 21.43M | 21.07M | 19.72M | 18.93M | 18.67M | 18.30M | 13.66M | 3.25M |
Strength Seen in InfuSystems Holdings, Inc. (INFU): Can Its 14.2% Jump Turn into More Strength?
InfuSystems Holdings, Inc. (INFU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
InfuSystem Announces $20 Million Stock Repurchase Program
ROCHESTER HILLS, Michigan, June 30, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today...
InfuSystem Enters Lymphedema Therapy Market
Providing pneumatic compression devices for last-mile patient care Providing pneumatic compression devices for last-mile patient care
InfuSystem to Participate at Craig-Hallum 18th Annual Institutional Investor Conference June 2, 2021
ROCHESTER HILLS, Michigan, May 27, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today...
InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q1 2021 Results - Earnings Call Transcript
InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q1 2021 Results - Earnings Call Transcript
InfuSystem Reports First Quarter 2021 Financial Results
Net Revenues: $24.5 million, a 14% increase Net Income: $0.7 million, a $1.1 million increase, Adjusted EBITDA: $6.2 million, a 51% increase, and Adjusted EBITDA margin of 25.2%, a 6.3% increase Company Reaffirms Full Year 2021 Guidance
InfuSystem to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
Investor Conference Call to be held 9:00 a.m. Eastern Time Investor Conference Call to be held 9:00 a.m. Eastern Time
InfuSystem Acquires OB Healthcare Corporation, Expanding DME Services Platform in Acute Care
ROCHESTER HILLS, Michigan, April 21, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced...
InfuSystem's Continued Execution Could Lead It To Double
InfuSystem's Continued Execution Could Lead It To Double
InfuSystem to Present at Sidoti's Spring 2021 Virtual Conference March 25, 2021
Investor Presentation to be held 9:15 a.m. Eastern Time Investor Presentation to be held 9:15 a.m. Eastern Time
Source: https://incomestatements.info
Category: Stock Reports